Literature DB >> 1676478

Screening dyspepsia by serology to Helicobacter pylori.

G M Sobala1, J E Crabtree, J A Pentith, B J Rathbone, T M Shallcross, J I Wyatt, M F Dixon, R V Heatley, A T Axon.   

Abstract

Owing to limited endoscopy resources, various screening strategies for endoscopy have been proposed. Helicobacter pylori can be detected with high sensitivity and specificity by serology, and therefore we assessed the effects on diagnostic accuracy and endoscopic workload of a policy of screening clinic patients with dyspepsia before endoscopy by a strategy based on age, Helicobacter pylori serology, and use of non-steroidal anti-inflammatory drugs. 1153 patients were studied, of whom 842 were of known histological H pylori status (histology group) and 293 had serum assessed prospectively by in-house and commercial ELISAs for detection of IgG antibodies to H pylori. Overall, the screening strategy would have reduced endoscopy workload by 23.3% (95% confidence interval 20.9-25.8%) and would have had a sensitivity for detection of peptic ulcer of 97.4% (94.5-99.1%). No peptic ulcer or malignant disease was missed in the patients studied prospectively, but 6 of 192 peptic ulcers in the histology group would have been missed. A policy of screening young dyspeptic patients for H pylori by serology is more sensitive than symptom-based screening strategies, and may have an important role in reducing endoscopy workload.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676478     DOI: 10.1016/0140-6736(91)90085-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  65 in total

1.  Non-invasive testing for Helicobacter pylori.

Authors:  M A Stone
Journal:  Postgrad Med J       Date:  1999-02       Impact factor: 2.401

Review 2.  Randomised controlled trials in primary care: case study.

Authors:  S Wilson; B C Delaney; A Roalfe; L Roberts; V Redman; A M Wearn; F D Hobbs
Journal:  BMJ       Date:  2000-07-01

Review 3.  Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.

Authors: 
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

4.  The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients.

Authors:  K E McColl; A el-Nujumi; L Murray; E el-Omar; D Gillen; A Dickson; A Kelman; T E Hilditch
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

Review 5.  An assessment of serological tests for detection of Helicobacter pylori.

Authors:  H von Wulffen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-07       Impact factor: 3.267

6.  Effect of antimicrobial therapy on the specific serological response to Helicobacter pylori infection.

Authors:  Y Glupczynski; A Burette; H Goossens; C DePrez; J P Butzler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-07       Impact factor: 3.267

7.  Evaluation of a commercially available complement fixation test for diagnosis of Helicobacter pylori infection and for follow-up after antimicrobial therapy.

Authors:  H Goossens; Y Glupczynski; A Burette; C Van den Borre; C DePrez; J Bodenmann; A Keller; J P Butzler
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

8.  Age-dependent accuracy of Helicobacter pylori antibody assays for adults, with special emphasis on atrophic gastritis.

Authors:  A Salomaa-Räsänen; T U Kosunen; J Mattila; S Sarna; H Rautelin
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

Review 9.  Role of Helicobacter pylori in gastrointestinal disease: implications for primary care of a revolution in management of dyspepsia.

Authors:  B C Delaney
Journal:  Br J Gen Pract       Date:  1995-09       Impact factor: 5.386

10.  Serological diagnosis of Helicobacter pylori--evaluation of four tests in the presence or absence of non-steroidal anti-inflammatory drugs.

Authors:  A S Taha; J Reid; P Boothmann; C G Gemmell; F D Lee; R D Sturrock; R I Russell
Journal:  Gut       Date:  1993-04       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.